Is Vemurafenib a targeted drug?

Vemurafenib (Vemurafenib) is the first molecularly targeted therapy approved in the United States and Europe for the treatment of advanced melanoma. Its mechanism of action includes selective inhibition of mutated BRAF V600E kinase, resulting in reduced signaling through the abnormal mitogen-activated protein kinase (MAPK) pathway. Its efficacy is limited to melanomas carrying the BRAF V600E mutation, which is found in about 50% of melanomas.

About half of melanomas have changes in the BRAF gene, which means the cells are making too much of the BRAF protein. This protein allows cancer cells to grow and divide. Vemurafenib works by targeting this protein, thereby slowing or stopping the development of cancer cells. In a randomized phase III trial, it was superior to dacarbazine in the first-line treatment of advanced melanoma, with an overall response rate (ORR) of 48%, an estimated 6-month progression-free survival (PFS) of 5.3 months, and a 12-month overall survival (OS) rate of 55%, which was statistically better than 43%. Vemurafenib is generally well tolerated, but its use may cause skin tumors such as squamous cell carcinoma (SCC) and keratoacanthoma (KA). These lesions can be safely resected without requiring discontinuation or dose reduction.

Vemurafenib The original drug has been launched in China and has entered the scope of medical insurance. The price of 240mg*56 tablets per box may be around 7,000 yuan, which is very expensive. The Turkish version of Vemurafenib Original drug listed overseas, specifications240mg*56 tablets, may cost more than 2,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively cheap. There is currently no generic version of Vemurafenib on the market. For more drug information and specific prices, please consult a medical consultant.